European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

{
  "signal_id": "3537af76-a0a3-18b2-e283-46199ce6477e",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-21T14:33:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/21/3365625/0/en/european-commission-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide.html",
    "title": "European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide",
    "excerpt": "Johnson & Johnson introduces the first IL-23R targeted oral peptide that can deliver skin clearance and a favourable safety profile in a once-daily pill. 1,2 ICOTYDE™ (icotrokinra) offers an innovative new option for eligible patients with moderate-to-severe plaque psoriasis to address patients cycling on topical therapies in need of systemic treatment. 1,2 BEERSE, BELGIUM (21 Sept 2026) – Johnson & Johnson today announced that the European Commission (EC) has granted approval for the Marketing Authorisation of ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of adults and adolescent patients (aged ≥12 years and weighing ≥40 kg) with moderate-to-severe plaque psoriasis (Pso) who are candidates for systemic therapy. 1 Icotrokinra is the first targeted oral peptide that precisely blocks the IL-23 receptor. 2,3,4 “For many people living with moderate-to-severe plaque psoriasis, the burden of disease remains substantial, but currently available systemic treatments do not consistently meet patients' treatment needs. There remains an ongoing unmet need for additional treatment options, regardless of route of administration.” said Lluís Puig, Professor of Dermatology, Universitat Autònoma de Barcelona. a “The approval of icotrokinra marks an important evolution in plaque psoriasis treatment. As the first targeted oral peptide designed to...",
    "product": "ICOTYDE",
    "summary": "Johnson & Johnson has received approval from the European Commission for its new oral peptide drug, ICOTYDE™ (icotrokinra), for the treatment of moderate-to-severe plaque psoriasis in adults and adolescents.",
    "location": "Beerse, Belgium",
    "planning": false,
    "image_url": "https://ml.globenewswire.com/Resource/Download/85723da3-163a-4a4d-bb36-0e46ec3998e6",
    "confidence": 0.95,
    "product_data": {
      "name": "ICOTYDE",
      "full_text": "ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-09-21T14:33:00Z",
    "location_data": [
      {
        "city": "Beerse",
        "state": "Antwerp",
        "region": "Western Europe",
        "country": "Belgium",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-21",
    "article_sentence": "Johnson & Johnson today announced that the European Commission (EC) has granted approval for the Marketing Authorisation of ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of adults and adolescent patients (aged ≥12 years and weighing ≥40 kg) with moderate-to-severe plaque psoriasis (Pso) who are candidates for systemic therapy."
  }
}

curl https://signals.autobound.ai/v1/signals/3537af76-a0a3-18b2-e283-46199ce6477e \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'